Eligibility

Getting Prescribed as a Young Adult: BMI, Age, and Eligibility Rules Explained

FDA eligibility criteria don't restrict by age, but prescriber reluctance and borderline BMI create real friction for younger patients. The eligibility framework, comorbidity documentation, and off-label options.

7 min read 2026 · glp-1prescriptions.com

Young adults (18–35) trying to get a GLP-1 prescription encounter specific eligibility questions: BMI requirements, whether being young is a factor, what to do when you're below the BMI cutoff but have metabolic concerns. Here's how eligibility actually works for younger patients.

The FDA-approved eligibility criteria (unchanged for age)

FDA approval for Wegovy and Zepbound applies to adults with: BMI ≥30 kg/m² (obesity), OR BMI ≥27 with at least one weight-related comorbidity. Age is not a criterion — there's no minimum age restriction for adult GLP-1 obesity prescribing beyond the general adult threshold (18+). Adolescent prescribing (12–17) is covered under separate pediatric approvals.

The 'young and healthy' objection

Some prescribers are reluctant to prescribe GLP-1s to patients in their 20s without significant metabolic disease. This is clinical judgment, not a regulatory requirement — the BMI criteria are met or not regardless of age. If one provider declines, another may prescribe based on the same clinical picture.

When BMI is borderline (27-30)

If your BMI is 27-30, you need a qualifying comorbidity. These are the most commonly documented:

  • Hypertension (including pre-hypertension in some clinical judgment)
  • Elevated fasting glucose or insulin resistance / pre-diabetes (A1C 5.7-6.4%)
  • Dyslipidemia (high LDL, low HDL, high triglycerides)
  • Sleep apnea (diagnosed or with clinical suspicion)
  • Polycystic ovary syndrome (PCOS) with documented androgenic or metabolic features
  • Non-alcoholic fatty liver disease (MASLD/MAFLD)

A lab panel establishing any of these — particularly A1C showing pre-diabetes — creates the comorbidity documentation needed for prescribing at BMI 27-30.

Off-label prescribing for lower BMI

For patients below BMI 27, off-label prescribing exists but is less common through mainstream telehealth platforms. Platforms with a longevity or metabolic health framing (Ageless, for example) may be more willing to evaluate the full metabolic picture rather than strictly applying BMI cutoffs.

Verified telehealth providers

Sesame Care$175 commission

BMI and eligibility evaluation. Licensed providers who can document comorbidities.

Get started →
Ageless$300 commission

Metabolic health framing — evaluates full picture beyond BMI threshold.

Get started →
Medical disclaimer: This content is for informational purposes only. Always consult a licensed healthcare provider before starting, changing, or stopping any medication. Affiliate disclosure: Links labeled "Paid link" are paid partnerships. This site earns a commission at no additional cost to you.
Free Download

The GLP-1 Cost & Provider Comparison Guide

10 pages breaking down real all-in monthly costs, what drives price differences between providers, and the questions to ask before you commit.